Supported by:
**All Information is Subject to Change**
Wednesday, November 29th, 2023
*All times listed in EST
Click Here to View Speaker Bios
9:00 AM to 9:15 AMWelcome, Logistics, and Introduction |
|
|---|---|
On behalf of CRS - Symposium Co-Chairs:Dr. Filippos Kesisoglou, MSc, PhDMerck, USA Dr. Liping Zhou, PhDAstraZeneca, USA Dr. Manuel Sanchez-Felix, PhDHalozyme, USA
|
   |
9:15 AM to 10:45 AMSession 1A: Biopharmaceutical Challenges, Discovery Chemistry and Preclinical Screens/Studies |
|
Overview of the Challenges and Achievements in Oral Administration of PeptidesDr. David Brayden, Ph.D.University College Dublin, Ireland 45 minutes
|
 |
A Biopharmaceutics Perspective on Oral Delivery of Peptides,
|
|
10:45 AM to 11:00 AMBREAK |
|
11:00 AM to 12:30 PMSession 1A (Contd.): Biopharmaceutical Challenges, Discovery Chemistry and Preclinical Screens/Studies |
|
Regional Delivery of MAB and ScreensDr. Vipul YadavIntract Pharma, UK 30 minutes |
 |
In-vitro Cellular AssaysRebecca CarrierNortheastern University, USA 30 minutes |
 |
Permeability MechanismDr. Karthik Nagapudi, PhDGenentech, USA 30 minutes |
 |
12:30 PM to 1:00 PMQ&A Session |
|
|---|---|
1:00 PM to 1:15 PMWelcome, Introduction, and Logistics - Co-Chair Liping Zhou |
|
1:15 PM to 2:45 PMSession 1B: Formulation/Screens and Ingestible Devices |
|
Formulation Peptide ScreeningDr. John Gleeson, PhDMerck, USA 30 minutes |
 |
HT Screening Formulation DesignThomas Von Erlach, PhDVivTex, USA 30 minutes |
 |
Ingestible Oral DevicesDr. Sharat Singh, PhDBiora, USA 30 minutes |
 |
2:45 PM to 3:15 PMQ&A Session |
|
3:15 to 3:30 PMClosing Remarks - Co-Chair Liping Zhou |
|
Thursday, November 30th, 2023
*All times listed in EST
9:00 AM to 9:15 AMWelcome, Introduction, and Logistics - Co-Chair Manuel Sanchez-Felix |
|
|---|---|
9:15 AM to 10:45 AMSession 2A: Clinical Translation |
|
Overview of Peptide Oral DeliveryDr. Puneet Tyagi, PhDAstraZeneca, USA 30 minutes |
 |
Oral Oligonucleotide DeliveryDr. Nigel Davies, PhDAstraZeneca, SE 30 minutes |
 |
Oral Monoclonal Antibody Delivery – A Reality CheckProf. Randall Mrsny, PhDUniversity of Bath, UK 30 minutes |
 |
10:45 AM to 11:00 AMBREAK |
|
11:00 AM to 12:15 PMSession 2A (Contd.): Clinical Translation |
|
Oral Semaglutide: From Concept to RealityDr. Stephen T. Buckley, PhDNovo Nordisk, USA 30 minutes |
 |
MK-0616: An Oral Macrocyclic Peptide Inhibitor of PCSK9Dr. Douglas Johns, PhD, FAHAMerck, USA 30 minutes |
 |
Symposium Summary and OverviewDr. Manuel Sanchez-FelixHalozyme 15 minutes |
 |
12:15 PM to 12:45 PMQ&A Session |
|
12:45 PM to 1:00 PMClosing Remarks - Co-Chair Manuel Sanchez-Felix |
|
